Our first and most advanced program is a retinal cell therapy to treat Retinitis Pigmentosa (RP), a debilitating inherited blindness disease affecting 1 in 4,000 people worldwide. Eventually it could be used to treat any cone or rod-based retinal diseases.
Current treatments for RP are limited to one single-mutation gene therapy with few eligible patients. For the others, there are no treatment options.
ALD01 could revolutionize RP treatment, offering a mutation agnostic option for almost all patients.
What’s more, ALD01 is supported by highly promising preclinical data and boasts numerous advantages over other RP cell therapies in development.
Heart failure (HF) is the most common cause of death worldwide. But current treatment options are often invasive and/or expensive, or just treat the symptoms.
ALD02 will be our second program, a cardiac cell therapy that has also shown promising preclinical data and aims to restore heart function.
Traditional approaches to bringing cell therapies to market are fraught with challenges — from high-risk development and unpredictable manufacturing processes to unreliable income models. So, we developed the AlderEdge, a unique drug development philosophy that de-risks the development of cell therapies. By keeping the commercial product in mind from the start, the AlderEdge approach de-risks development, helping to bring advanced cell therapies to market, faster, and more reliably.
Interested in shaping the evolution of regenerative medicine? Get in touch to find out more.
